@mac1
Discussion
[…] Because
we did not collect participant samples prior to time point 1, it is not known
how many of those participants had SARS-CoV-2 IgG antibodies prior to
vaccination. In this cohort, there were too few individuals to determine
whether there was a significant difference in average SARS-CoV-2 IgG antibody
titers at any time point following both vaccination doses.
This study had several limitations. Due to our
enrollment of health care workers, the
average age of participants was low, with only 8 participants over the age
of 50 years and only 1 participant over the age of 65 years. Participants were
not monitored during specimen collection after the first time point, but the
ability of participants to follow instructions for unobserved collection was
validated internally prior to sample collection. All participants received the
Moderna COVID-19 vaccine, and further research is needed to understand the
longitudinal antibody response in oral or nasal mucosal fluid following other
COVID-19 vaccines, such as the mRNA Pfizer/BioNtech vaccine and the viral
vector Janssen vaccine. It is not yet
known how oral mucosal fluid antibody titers are directly comparable to serum
titers for the protection of infection or disease. […]
Quantification of
SARS-CoV-2 IgG antibodies in oral fluid mucosal specimens of non-vaccinated
individuals with previous SARS-CoV-2 infection demonstrated antibody
persistence through 3.5 months without a significant decline. This may suggest persistence of SARS-CoV-2 IgG antibodies in oral
mucosal fluid post-vaccination.
Detection of
persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper
respiratory tract specimens following COVID-19 mRNA vaccination